Myostatin is an endogenous, negative regulator of muscle growth determining both muscle
fiber number and size. The myostatin pathway is conserved across diverse species ranging …

Background Myostatin inhibition is a promising therapeutic strategy to maintain muscle mass
in a variety of disorders, including the muscular dystrophies, cachexia, and sarcopenia …

Sarcopenia is the progressive loss of skeletal muscle mass and function with advancing
age, leading to reduced mobility and quality of life. We tested the hypothesis that antibody …

There is much interest in developing anti-myostatin agents to reverse or prevent muscle
atrophy in adults, so it is important to characterize the effects of reducing myostatin activity …

Myostatin is a negative regulator of muscle mass whose inhibition has been proposed as a
therapeutic strategy for muscle-wasting conditions. Indeed, blocking myostatin action …

Suppression of the myostatin (GDF‐8) pathway has emerged as an important therapeutic
paradigm for muscle‐wasting disorders. In this study, we conducted a translational …

Since its discovery in 1997, myostatin has quickly been established as a key regulator of
skeletal muscle mass. Recent developments strengthen the idea that myostatin will be an …

Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative disease leading to
motor neuron cell death, but recent studies suggest that non-neuronal cells may contribute …

Skeletal muscle fibrosis is a major pathological hallmark of chronic myopathies in which
myofibers are replaced by progressive deposition of collagen and other extracellular matrix …

Myostatin, a member of the transforming growth factor beta (TGF‐β) superfamily that is
highly expressed in skeletal muscle, was first described in 1997. It has been known that loss …